Naples Global Advisors LLC Takes Position in Danaher Corporation $DHR

Key Points

• Naples Global Advisors LLC acquired a new stake in Danaher Corporation, purchasing 1,363 shares valued at approximately $270,000 during the second quarter.
• Danaher reported a quarterly EPS of $1.80, surpassing analyst expectations, with revenue of $5.94 billion, reflecting a 3.4% increase year-over-year.
• The company declared a quarterly dividend of $0.32 per share, which will be paid to shareholders on October 31st, representing an annualized yield of 0.6%.

Naples Global Advisors LLC purchased a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,363 shares of the conglomerate's stock, valued at approximately $270,000.

A number of other large investors also recently modified their holdings of the company. Hills Bank & Trust Co lifted its stake in shares of Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after acquiring an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC lifted its stake in shares of Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate's stock valued at $236,000 after acquiring an additional 53 shares during the last quarter. Sageworth Trust Co lifted its stake in shares of Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after acquiring an additional 54 shares during the last quarter. 1834 Investment Advisors Co. raised its position in Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock worth $342,000 after purchasing an additional 54 shares during the last quarter. Finally, Bruce G. Allen Investments LLC raised its position in Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock worth $92,000 after purchasing an additional 54 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on DHR shares. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Evercore ISI lowered their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Bank of America lowered their target price on Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a research report on Monday, September 22nd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Danaher in a research report on Saturday, September 27th. Finally, Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $245.91.

Danaher Stock Performance

Shares of DHR opened at $215.05 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a 50-day moving average of $200.19 and a 200-day moving average of $197.42. The company has a market cap of $153.98 billion, a PE ratio of 45.75, a P/E/G ratio of 3.00 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's payout ratio is currently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.